MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Akcijų sąrašas・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.38 2.7

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.36

Max

0.4

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-15M -35M
Pardavimai	-18M 581K
Pelno marža	-6,012.048
Darbuotojai	183
EBITDA	-15M -33M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+913.51% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-16

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-39M 135M
Ankstesnė atidarymo kaina	-2.32
Ankstesnė uždarymo kaina	0.38

Naujienos nuotaikos

By Acuity

92%

341 / 360 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

0.5207 / 0.7223 Palaikymas ir pasipriešinimas

Sangamo Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-21 23:49; UTC

Pagrindinės rinkos jėgos

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026-01-21 21:12; UTC

Pagrindinės rinkos jėgos

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 21:00; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026-01-21 20:29; UTC

Pagrindinės rinkos jėgos

Chip Makers Gain After Trump Calls Off European Tariffs

2026-01-21 20:04; UTC

Pagrindinės rinkos jėgos

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026-01-21 23:34; UTC

Rinkos pokalbiai

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026-01-21 22:39; UTC

Uždarbis

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026-01-21 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-21 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-21 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026-01-21 21:19; UTC

Uždarbis

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026-01-21 20:45; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026-01-21 20:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026-01-21 20:31; UTC

Rinkos pokalbiai

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026-01-21 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026-01-21 20:27; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-21 20:27; UTC

Rinkos pokalbiai

Was It a 'TACO' Event? -- Market Talk

2026-01-21 20:26; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026-01-21 20:23; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026-01-21 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026-01-21 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Group Agrees to Buy Allfunds

2026-01-21 20:08; UTC

Uždarbis

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026-01-21 20:03; UTC

Rinkos pokalbiai

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026-01-21 19:51; UTC

Rinkos pokalbiai

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026-01-21 19:43; UTC

Rinkos pokalbiai

U.S. Ethanol Production Expected to Slip -- Market Talk

2026-01-21 19:31; UTC

Rinkos pokalbiai

Gold Settles at Fresh All-Time High -- Market Talk

2026-01-21 19:24; UTC

Uždarbis

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026-01-21 19:10; UTC

Rinkos pokalbiai

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026-01-21 18:57; UTC

Rinkos pokalbiai

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sangamo Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

913.51% į viršų

12 mėnesių prognozė

Vidutinis 3.75 USD 913.51%

Aukščiausias 10 USD

Žemiausias 1 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sangamo Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Sangamo Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.5207 / 0.7223Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

341 / 360 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.